Kubra Khadeja-Tul, Akhter Mohammad S, Apperley Kaitlyn, Barabutis Nektarios
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Endocrines. 2022 Dec;3(4):813-820. doi: 10.3390/endocrines3040067. Epub 2022 Dec 9.
Growth hormone-releasing hormone (GHRH) and its receptors are expressed in a variety of human cancers, and have been involved in malignancies. GHRH antagonists (GHRHAnt) were developed to suppress tumor progression and metastasis. Previous studies demonstrate the involvement of reactive oxygen species (ROS) in cancer progression. Herein, we investigate the effect of a commercially available GHRH antagonist, namely JV-1-36, in the redox status of the A549 human cancer cell line. Our results suggest that this peptide significantly reduces ROS production in those cells in a time-dependent manner and counteracts HO-induced ROS. Our study supports the anti-oxidative effects of JV-1-36 and contributes in our knowledge towards the in vitro effects of GHRHAnt in cancers.
生长激素释放激素（GHRH）及其受体在多种人类癌症中表达，并与恶性肿瘤有关。开发生长激素释放激素拮抗剂（GHRHAnt）以抑制肿瘤进展和转移。先前的研究表明活性氧（ROS）参与癌症进展。在此，我们研究了一种市售的生长激素释放激素拮抗剂JV-1-36对A549人癌细胞系氧化还原状态的影响。我们的结果表明，这种肽以时间依赖性方式显著降低这些细胞中的ROS产生，并抵消过氧化氢诱导的ROS。我们的研究支持JV-1-36的抗氧化作用，并有助于我们了解GHRHAnt在癌症中的体外作用。
